At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,751 enrolled
Drug / intervention
norelgestromin + ethinyl estradioldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17deacetyl-norgestimate and Ethinyl Estradiol.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Oct 12, 2005·Updated Nov 17, 2010
In Brief
A Phase 3 clinical trial evaluating norelgestromin + ethinyl estradiol for Contraception and Female Contraception. Completed, enrolled 1,751 participants.
Detailed Summary
The purpose of the study is to evaluate the contraceptive efficacy, safety, cycle control, and compliance with the transdermal contraceptive system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception, Female Contraception
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 1997
Study CompletionOct 1999
First PostedOct 2005
TodayJul 2026
First PostedOct 12, 2005
Enrollment StartNov 1, 1997
Study CompletionOct 1, 1999
TodayJul 2, 2026
Posted 20.7 years ago
Interventions
norelgestromin + ethinyl estradioldrug